These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30040928)

  • 1. Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms.
    Mishra A; Chandravanshi LP; Trigun SK; Krishnamurthy S
    Biochem Pharmacol; 2018 Sep; 155():479-493. PubMed ID: 30040928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease.
    Mishra A; Krishnamurthy S
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):429-444. PubMed ID: 31654086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
    Mishra A; Krishnamurthy S
    Neurotox Res; 2019 Apr; 35(3):542-562. PubMed ID: 30610666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
    Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV
    Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase and parkinsonism: lessons to learn.
    Marković I; Kresojević N; Kostić VS
    J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats.
    Hegazy MA; Maklad HM; Samy DM; Abdelmonsif DA; El Sabaa BM; Elnozahy FY
    Neurochem Int; 2017 Sep; 108():361-371. PubMed ID: 28527632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity.
    Mus L; Siani F; Giuliano C; Ghezzi C; Cerri S; Blandini F
    Neurobiol Dis; 2019 Apr; 124():289-296. PubMed ID: 30521842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.
    Siemeling O; Slingerland S; van der Zee S; van Laar T
    BMC Neurol; 2024 May; 24(1):146. PubMed ID: 38693511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
    Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
    Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
    Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H
    Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
    Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
    Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
    JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity.
    Yang J; Hertz E; Zhang X; Leinartaité L; Lundius EG; Li J; Svenningsson P
    Neurosci Lett; 2016 Jan; 611():51-8. PubMed ID: 26610904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Schapira AH
    Sci Rep; 2018 Jan; 8(1):1385. PubMed ID: 29362387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
    Kumari N; Agrawal S; Kumari R; Sharma D; Luthra PM
    Neurosci Lett; 2018 May; 675():74-82. PubMed ID: 29567422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.